A Phase 1 Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of A Vaccine-based Immunotherapy Regimen (Vbir) For Prostate Cancer (Pf-06753512)
Phase of Trial: Phase I
Latest Information Update: 02 Dec 2017
At a glance
- Drugs PF 6753512 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 31 Oct 2017 Planned End Date changed from 20 Apr 2019 to 11 Sep 2021.
- 31 Oct 2017 Planned primary completion date changed from 20 Apr 2019 to 20 Sep 2020.
- 09 Aug 2017 Status changed from suspended to recruiting.